GMAB (Genmab AS) Gross Margin % : 94.77% (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Genmab AS Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Genmab AS's Gross Profit for the three months ended in Dec. 2024 was $857 Mil. Genmab AS's Revenue for the three months ended in Dec. 2024 was $904 Mil. Therefore, Genmab AS's Gross Margin % for the quarter that ended in Dec. 2024 was 94.77%.

The historical rank and industry rank for Genmab AS's Gross Margin % or its related term are showing as below:

GMAB' s Gross Margin % Range Over the Past 10 Years
Min: 95.42 Med: 97.03 Max: 98.63
Current: 95.42

During the past 13 years, the highest Gross Margin % of Genmab AS was 98.63%. The lowest was 95.42%. And the median was 97.03%.

GMAB's Gross Margin % is ranked better than
92.96% of 739 companies
in the Biotechnology industry
Industry Median: 59.89 vs GMAB: 95.42

Genmab AS had a gross margin of 94.77% for the quarter that ended in Dec. 2024 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Genmab AS was 0.00% per year.

Genmab AS Gross Margin % Historical Data

The historical data trend for Genmab AS's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab AS Gross Margin % Chart

Genmab AS Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Gross Margin %

Get a 7-Day Free Trial

98.63

95.42

Genmab AS Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Gross Margin %	Get a 7-Day Free Trial															97.35	95.53	96.48	95.07	94.77

Competitive Comparison of Genmab AS's Gross Margin %

For the Biotechnology subindustry, Genmab AS's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genmab AS's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Genmab AS's Gross Margin % falls into.

Save Embed

;

Save Embed

;

Genmab AS Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Genmab AS's Gross Margin for the fiscal year that ended in Dec. 2024 is calculated as

Gross Margin % (A: Dec. 2024 )	=	Gross Profit (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	2884.1	/	3022.423
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(3022.423 - 138.302)	/	3022.423
	=	95.42 %

Genmab AS's Gross Margin for the quarter that ended in Dec. 2024 is calculated as

Gross Margin % (Q: Dec. 2024 )	=	Gross Profit (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	857.1	/	904.368
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(904.368 - 47.317)	/	904.368
	=	94.77 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Genmab AS (NAS:GMAB) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Genmab AS had a gross margin of 94.77% for the quarter that ended in Dec. 2024 => Durable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

Genmab AS Gross Margin % Related Terms

Thank you for viewing the detailed overview of Genmab AS's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Genmab AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (NAS:GMAB) » Definitions » Gross Margin %

Comparable Companies

Traded in Other Exchanges

GNMSF:USA GMAB:Mexico GMABc:UK 0MGB:UK GMAB:Denmark GE91:Germany GMAB:Austria

Address

Carl Jacobsens Vej 30, Valby, DNK, 2500

Website

https://www.genmab.com

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.